News Column

Regulator Launches Learning Module on Oral Anticoagulants

August 5, 2014

LONDON, Aug. 5 -- The British Medicines and Healthcare Products Regulatory Agency issued the following news release:

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched an online learning module for healthcare professionals on reducing the side effects of oral anticoagulants.

Anticoagulants are vital medicines for treating and preventing blood clots. However, if the patient is not managed correctly their side effects can lead to a small number of people needing hospital treatment. With the right precautions, many of these side effects can be prevented.

Designed for doctors, nurses and pharmacists, the interactive programme takes the learner through key points about these medicines, how to manage the risks and, importantly, how to make sure patients get the most benefit from these medicines.

Dr June Raine, director of MHRA's Vigilance and Risk Management of Medicines division, said:

"Anticoagulant medicines are vital for treating and preventing blood clots but in some cases, as with any effective medicine, there can be side effects.

"This e-learning module will help clinicians identify and proactively manage the risks with anticoagulant medication."

Dr Angela Thomas, director of the Haemophilia Centre at Edinburgh Hospital said:

"The MHRA has succeeded in delivering excellent material in a user-friendly and very engaging manner. This makes learning about anticoagulants enjoyable. The quiz at the end is a useful test of the learning."

On successful completion of the module, learners will be able to download a certificate to show they have completed the course which has been approved for continuing professional development (CPD) by the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.

Notes to Editor

1. Oral anticoagulants e-learning module

2. MHRA is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. Underpinning all our work lies robust and fact-based judgements to ensure that the benefits justify any risks. The MHRA is a centre of the Medicines and Healthcare Products Regulatory Agency which also includes the National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD). The MHRA is an executive agency of the Department of Health.

TNS 18EstebanLiz-140806-30FurigayJane-4820383 30FurigayJane

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Targeted News Service

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters